Figure 3.
Molecular study of case 1. Sanger sequencing showed that the KRAS G12V mutation was present in both the serous borderline tumor/non-invasive low-grade serous carcinoma (SBT/niLGSC) and the mesonephric-like adenocarcinoma (MLA), indicating their clonal origin. Star (*) indicates mutational site.